Table 3 Distribution of genomic alterations associated with normal-like (NL) and other-type (OT) tumors
IDH-WT gliomas (n = 238) | NL (n = 14) | OT (n = 224) | p value (Fisher’s test) |
|---|---|---|---|
TERT promoter status | |||
Mutant | 1 (7.1%) | 62 (27.7%) | |
WT | 10 (71.4%) | 9 (4%) | 4.2e−07 |
Unknown | 3 (21.4%) | 153 (68.3%) | |
Chr 7 gain/chr 10 loss | |||
Gain chr 7 and loss chr 10 | 2 (14.3%) | 150 (67%) | |
No combined CNA | 11 (78.6%) | 70 (31.2%) | 0.00022 |
Unknown | 1 (7.1%) | 4 (1.8%) | |
BRAF V600E status | |||
Mutant | 1 (7.1%) | 2 (0.9%) | |
WT | 13 (92.9%) | 218 (97.3%) | 0.17 |
Unknown | 0 (0%) | 4 (1.8%) | |
BRAF-KIAA1549 fusion | |||
Fusion | 0 (0%) | 1 (0.4%) | |
WT | 14 (100%) | 217 (96.9%) | 1 |
Unknown | 0 (0%) | 6 (2.7%) | |
ATRX status | |||
Mutant | 0 (0%) | 8 (3.6%) | |
WT | 14 (100%) | 212 (94.6%) | 1 |
Unknown | 0 (0%) | 4 (1.8%) | |
EGFR | |||
EGFR amplification | 6 (42.9%) | 198 (88.4%) | 0.000082 |
EGFR deletion | 0 (0%) | 1 (0.4%) | |
WT | 8 (57.1%) | 24 (10.7%) | |
Unknown | 0 (0%) | 1 (0.4%) | |
FGFR1 | |||
FGFR1 amplification | 0 (0%) | 20 (8.9%) | 0.61 |
FGFR1 deletion | 1 (7.1%) | 29 (12.9%) | |
WT | 13 (92.9%) | 174 (77.7%) | |
Unknown | 0 (0%) | 1 (0.4%) | |
CDKN2A | |||
CDKN2A amplification | 0 (0%) | 6 (2.7%) | |
CDKN2A deletion | 5 (35.7%) | 166 (74.1%) | 0.0021 |
WT | 9 (64.3%) | 51 (22.8%) | |
Unknown | 0 (0%) | 1 (0.4%) | |
CDKN2B | |||
CDKN2B amplification | 0 (0%) | 7 (3.1%) | |
CDKN2B deletion | 5 (35.7%) | 164 (73.2%) | 0.0025 |
WT | 9 (64.3%) | 52 (23.2%) | |
Unknown | 0 (0%) | 1 (0.4%) | |
MYB | |||
MYB amplification | 0 (0%) | 6 (2.7%) | 0.12 |
MYB deletion | 1 (7.1%) | 69 (30.8%) | |
WT | 13 (92.9%) | 148 (66.1%) | |
Unknown | 0 (0%) | 1 (0.4%) | |
MYBL1 | |||
MYBL1 amplification | 0 (0%) | 22 (9.8%) | 0.68 |
MYBL1 deletion | 1 (7.1%) | 25 (11.2%) | |
WT | 13 (92.9%) | 176 (78.6%) | |
Unknown | 0 (0%) | 1 (0.4%) | |
MGMT_promoter_status | |||
Methylated | 4 (28.6%) | 72 (32.1%) | |
Unmethylated | 10 (71.4%) | 121 (54.0%) | 0.58 |
Unknown | 0 (0.0%) | 31 (13.8%) | |